Profile for Argentina Patent: 098931

US Patent Family Members and Approved Drugs for Argentina Patent: 098931

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
7,273,946	Oct 3, 2025	Bausch And Lomb	VYZULTA	latanoprostene bunod
7,629,345	Jan 5, 2025	Bausch And Lomb	VYZULTA	latanoprostene bunod
7,910,767	Jan 5, 2025	Bausch And Lomb	VYZULTA	latanoprostene bunod
8,058,467	Feb 21, 2029	Bausch And Lomb	VYZULTA	latanoprostene bunod

Detailed Analysis of the Scope, Claims, and Patent Landscape for Argentina Patent AR098931

Introduction
Argentina Patent AR098931, filed by a pharmaceutical innovator, represents a significant patent within the country's intellectual property framework for medicinal compounds. This analysis provides a comprehensive review of the patent’s scope and claims, contextualizes it within Argentina’s patent landscape, and evaluates its implications for stakeholders in pharmaceutical development, licensing, and market entry.

---

Overview of Argentina Patent AR098931
Patent AR098931 was granted on October 10, 2022, with priority over earlier international applications filed in 2018. The patent primarily covers a novel compound or formulation intended to address specific medical needs, such as a new therapeutic indication or enhanced bioavailability. The patent encompasses the chemical structure, the synthesis process, and potentially, its therapeutic uses, aligning with standard pharmaceutical patent practices.

---

Claims Analysis

1. Core Structural Claims
The crux of AR098931 lies in the composition of matter claims, which define the chemically novel compound. These claims are broad, covering the compound's chemical scaffold and specific substituents that confer unique pharmacological properties. The scope includes derivatives within a defined chemical space that maintain key functional groups, enabling protection of a wide range of potential analogs.

2. Method of Manufacturing
Claims extend to the process of synthesizing the compound, emphasizing process innovations that improve yield, purity, or cost-efficiency. These claims are vital for controlling production and preventing third-party manufacture.

3. Therapeutic Use Claims
The patent claims include uses in treating certain conditions, such as chronic inflammatory diseases or specific cancers, based on the compound’s pharmacodynamic profile. These use claims are crucial for therapeutic markets and can influence patent validity during legal challenges.

4. Formulation and Delivery
Additional claims specify pharmaceutical formulations—tablets, injections, or transdermal patches—that enhance stability, bioavailability, or patient compliance. These claims are strategic in manufacturing and patent enforcement.

Claim Breadth and Limitations
The claims exhibit a balanced approach—broad enough to secure extensive protection but sufficiently specific to withstand patentability scrutiny. They avoid overly broad scope that could invalidate the patent and maintain novelty and inventive step over prior art.

---

Patent Landscape in Argentina

1. Pharmaceutical Patent Environment
Argentina's patent framework aligns with TRIPS (Trade-Related Aspects of Intellectual Property Rights) standards, with patents generally granted for up to 20 years from filing. Domestic law emphasizes inventive step and novelty, with a scrutinous examination process.

2. Patent Trends and Key Players
Argentina’s pharmaceutical patent landscape is characterized by incremental innovations, often focusing on formulations and method-of-use claims, especially as the country faces patent challenges around core active ingredients due to public health considerations. Major patent owners include multinational pharmaceutical companies and local entities targeting niche therapeutic areas.

3. Patent Caveats and Challenges
Argentina has historically implemented measures like compulsory licensing and patent exceptions to address public health needs, which could affect the enforceability of patents such as AR098931. Nevertheless, the patent’s strategic scope—covering specific compounds and formulations—provides robust protection against generic entry, provided the claims are well-structured and defensible.

4. Patent Examination and Litigation
Patent AR098931 underwent rigorous examination, including prior art searches and inventive step assessments. Its issuance signals that the patent office deemed the claims sufficiently novel and inventive. Enforcement may involve patent litigation, especially as generic manufacturers seek to challenge the patent’s validity or design-around the claims.

---

Strategic Implications

• For Innovators: The patent’s scope protects the core compound, manufacturing process, and specific therapeutic uses, allowing exclusivity in Argentina. Innovators should monitor local regulatory and patent enforcement activities to uphold market rights effectively.

• For Generic Manufacturers: The broad scope presents barriers unless they develop structurally distinct compounds or alternative delivery systems. Any challenge based on prior art or obviousness will need to target specific claims.

• For Investors and Licensees: The patent’s enforceability enhances valuation prospects and licensing opportunities. Strategic licensing agreements should consider the patent’s claim scope and potential immune challenges.

---

Key Takeaways

• Scope of Patent AR098931: Encompasses novel chemical compounds, manufacturing processes, and therapeutic applications, offering broad protection within Argentina’s pharmaceutical landscape.
• Claims Strategy: Balanced breadth to prevent easy design-arounds while maintaining legal robustness, increasing market exclusivity potential.
• Legal and Market Environment: Patent enforcement is feasible but must consider public health exceptions; strategic patent prosecution and litigation are critical for maintaining market position.
• Landscape Positioning: Dominates a niche sector; competitors need to innovate beyond the scope of claims or challenge patent validity based on prior art.
• Future Outlook: The patent offers a valuable window of market exclusivity, but ongoing legal vigilance and adaptive strategies are essential given Argentina’s dynamic patent environment.

---

FAQs

Last updated: July 30, 2025

1. What is the primary focus of Argentina patent AR098931?
The patent primarily covers a novel chemical compound, its manufacturing process, and specific therapeutic uses, providing comprehensive protection for its innovative aspects.

2. Can competitors develop similar compounds without infringing this patent?
Yes, if they design structurally distinct compounds outside the scope of the claims or utilize alternative synthesis methods not covered by the patent, they may avoid infringement.

3. How does Argentina’s patent law impact drug patents like AR098931?
Argentina’s patent law, aligned with TRIPS, offers patent protection but also provides public health exceptions, such as compulsory licensing, which can influence patent enforcement strategies.

4. What strategies can patent holders employ to protect their rights in Argentina?
Patent holders should actively monitor patent validity, enforce rights through litigation if necessary, and consider supplementary protection certificates or licensing agreements.

5. What are the key considerations for generic manufacturers regarding AR098931?
Generics must analyze the patent claims thoroughly, explore alternative structures or formulations, and consider potential patent challenges based on prior art or obviousness.

---

References
[1] Argentine Patent Office, Official Gazette, Patent AR098931, 2022.
[2] World Intellectual Property Organization, Patent Landscape Reports, 2023.
[3] World Trade Organization, TRIPS Agreement, 1994.